CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2020	$ 35	$ 320,280	$ (347,352)	$ (27,037)
Beginning balance (in shares) at Dec. 31, 2020	34,765,280
Issuance of common stock, net of issuance cost	$ 9	37,616		37,625
Issuance of common stock, net of issuance cost (in shares)	8,749,999
Issuance of common stock under the Sales Agreement, net	$ 2	8,573		8,575
Issuance of common stock under the Sales Agreement, net (in shares)	1,867,552
Share-based compensation related to stock options		1,405		1,405
Share-based compensation related to restricted stock awards		970		970
Exercise of warrants (in shares)	173,816
Reacquisition of equity component of convertible notes		(12,019)		(12,019)
Equity component of convertible notes, net of transaction costs		12,027		12,027
Net income (loss)			(27,582)	(27,582)
Ending balance at Dec. 31, 2021	$ 46	368,852	(374,934)	(6,036)
Ending balance (in shares) at Dec. 31, 2021	45,556,647
Issuance of common stock under the Sales Agreement, net	$ 7	8,229		8,236
Issuance of common stock under the Sales Agreement, net (in shares)	7,473,038
Share-based compensation related to stock options		1,124		1,124
Share-based compensation related to restricted stock awards	$ 1	960		961
Share-based compensation related to restricted stock awards (in shares)	759,482
Exercise of warrants		2		2
Exercise of warrants (in shares)	1,000
Net income (loss)			(14,927)	(14,927)
Ending balance at Dec. 31, 2022	$ 54	379,167	(389,861)	(10,640)
Ending balance (in shares) at Dec. 31, 2022	53,790,167
Issuance of common stock under the Sales Agreement, net	$ 13	23,941		23,954
Issuance of common stock under the Sales Agreement, net (in shares)	12,560,150
Convertible notes conversions	$ 5	7,778		7,783
Convertible notes conversions (in shares)	4,691,623
Share-based compensation related to stock options		1,928		1,928
Share-based compensation related to restricted stock awards	$ 1	1,519		1,520
Share-based compensation related to restricted stock awards (in shares)	1,371,362
Exercise of warrants		712		712
Exercise of warrants (in shares)	538,822
Net income (loss)			8,312	8,312
Ending balance at Dec. 31, 2023	$ 73	$ 415,045	$ (381,549)	$ 33,569
Ending balance (in shares) at Dec. 31, 2023	72,952,124